www.neurologiepropraxi.cz / Neurol. praxi. 2023;24(4):264-267 / NEUROLOGIE PRO PRAXI 267 PŘEHLEDOVÉ ČLÁNKY Zlepšení kognitivních funkcí a zaměstnanosti u pacientů s relabující formou roztroušené sklerózy léčených okrelizumabem 3. Benedict RHB, Comi G, Oreja‑Guevara C, et al. Cognitive Improvements in Ocrelizumab‑Treated Patients withRelapsing ‑Remitting Multiple Sclerosis: 96-Week CASTING Study Data. Available from: https://medically.roche.com/global/en/ medical‑material.c5dd6233-0990-4770-9208-35fcfea91235. qr.html?cid=slprxx2210nexxectrims2022. 4. Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336-46. 5. Campbell J, Rashid W, Cercignani M, et al. Cognitive impairment among patients with multiple sclerosis: associations with employment and quality of life. Postgrad Med J. 2017;93(1097):143-147. 6. Castelo‑Branco A, Landfeldt E, Svedbom A, et al. Clinical course of multiple sclerosis and labour‑force absenteeism: a longitudinal population‑based study. Eur J Neu‑ rol. 2019;26(4):603–9. 7. Chen J, Taylor B, Palmer AJ, et al. Estimating MSrelated work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. Mult Scler. 2019;25(7):994-1004. 8. Dorstyn DS, Roberts RM, Murphy G, et al. Employment and multiple sclerosis: a meta‑analytic review of psychological correlates. J Health Psychol. 2019;24(1):38-51. 9. García‑Domínguez JM, Maurino J, Martínez‑Ginés ML, et al. Economic burden of multiple sclerosis in a population with low physical disability. BMC Public Health. 2019;19(1):609. 10. Glanz BI, Dégano IR, Rintell DJ, et al. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and healthrelated quality of life. Value Health. 2012;15(8): 1029-35. 11. Hauser SL, Bar‑Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-34. 12. Johnson KL, Yorkston KM, Klasner ER, et al. The cost and benefits of employment: a qualitative study of experiences of persons with multiple sclerosis. Arch Phys Med Reha‑ bil. 2004;85(2):201-9. 13. Julian LJ, Vella L, Vollmer T, et al. Employment in multiple sclerosis. Exiting and re‑entering the work force. J Neurol. 2008;255(9):1354-60. 14. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse‑Independent Progression vs Relapse‑Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020;77(9):1132-1140. 15. Landfeldt E, Castelo‑Branco A, Svedbom A, et al. Sick leave and disability pension before and after diagnosis of multiple sclerosis. Mult Scler. 2016;22(14):1859-66. 16. Lehmann AI, Rodgers S, Kamm CP, et al. Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross‑sectional citizen science study. J Neurol. 2020;267:3069-3082. 17. Marck CH, Aitken Z, Simpson S Jr, et al. Predictors of change in employment status and associations with quality of life: a prospective international study of people with multiple sclerosis. J Occup Rehabil. 2020;30(1):105-14. 18. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209-20. 19. Nicholas JA, Electricwala B, Lee LK, et al. Burden of relapsing‑remitting multiple sclerosis on workers in the US: a cross‑sectional analysis of survey data. BMC Neurol. 2019;19(1):258. 20. Povolo CA, Blair M, Mehta S, Rosehart H, et al. Predictors of vocational status among persons with multiple sclerosis. Mult Scler Relat Disord. 2019; 36:101411. 21. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169-80. 22. Reilly Associates. WPAI: SHP V2. 0. Available from: http:// www.reillyassociates.net/wpai_shp.html. 23. Rumrill P, Li J, Strauser D, et al. Personal, health and function, and career maintenance factors as determinants of quality of life among employed people with multiple sclerosis. Work. 2020;67(1):81-94. 24. Simmons RD, Tribe KL, McDonald EA. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management. J Neurol. 2010;257(6):926-36. 25. Strober L, DeLuca J, Benedict RH, et al. Symbol Digit Modalities Test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler. 2019;25(13): 1781-1790. 26. Strober LB, Bruce JM, Arnett PA, et al. A much needed metric: Defining reliable and statistically meaningful change of the oral version Symbol Digit Modalities Test (SDMT). Mult Scler Relat Disord. 2022;57:103405. 27. van Gorp DAM, van der Hiele K, Heerings MAP, et al. Cognitive functioning as a predictor of employment status in relapsing‑remitting multiple sclerosis: a 2-year longitudinal study. Neurol Sci. 2019;40(12):2555-2564. 28. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J. 2020;16(14):1816-21. 29. Weindel H, Benedict RHB, Comi G, et al. Employment and Cognitive Improvements in Ocrelizumab‑Treated Patients with Relapsing‑Remitting Multiple Sclerosis: 96Week CASTING Study Data. Dostupné na: https://medically.roche.com/global/en/medical‑material.6327f9d01652-4bcc‑b945-9dbefad807dd.qr.html?cid=slprxx2210nexxectrims2022. 30. Weinstock Z, Morrow S, Conway D, et al. Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. Mult Scler. 2022;28(7):1101-1111. PŘEDNÁŠKY Význam studie PEARL pro klinickou praxi – MUDr. Jolana Marková, FEAN Medication overuse headache a role anti-CGRP – MUDr. Petra Migaľová Lékové interakce migréna a RS – update – PharmDr. Josef Suchopár Výhody exibility podání fremanezumabu u našich pacientů – MUDr. Monika Záhumenská ODBORNÝ GARANT MUDr. Jolana Marková, FEAN Neurologická klinika, Fakultní Thomayerova nemocnice v Praze PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN prosinec 2022 až listopad 2023 dostupný na online.solen.cz On-line kurz pro praktické neurology Trendy v léčbě migrény 3 2022 ON LINE KURZ
RkJQdWJsaXNoZXIy NDA4Mjc=